Table 2.
Admission, in-hospital and discharge medical therapy.
| Total (N = 646) |
SGLT2-I users (N = 111) |
Non-SGLT2-I users (N = 535) |
P value | |
|---|---|---|---|---|
| Admission medical therapy | ||||
| Anti platelets, n (%) | 321 (49.7) | 60 (54.1) | 261 (48.8) | 0.312 |
| Anti coagulation, n (%) | 55 (8.5) | 6 (5.4) | 49 (9.2) | 0.197 |
| RAAS inhibitor, n (%) | 378 (58.5) | 69 (62.2) | 309 (57.8) | 0.391 |
| Diuretics, n (%) | 196 (30.3) | 31 (27.9) | 165 (30.8) | 0.543 |
| B-blockers, n (%) | 296 (45.8) | 55 (49.5) | 241 (45) | 0.386 |
| CCB, n (%) | 197 (30.5) | 35 (31.5) | 162 (30.3) | 0.794 |
| Statins, n (%) | 329 (50.9) | 61 [55] | 268 (50.1) | 0.351 |
| Low/moderate intensity | 238 (72.3) | 39 (63.9) | 199 (74.3) | 0.104 |
| High intensity | 91 (27.7) | 22 (36.1) | 69 (25.7) | |
| Ezetimibe, n (%) | 78 (12.1) | 15 (13.5) | 63 (11.8) | 0.609 |
| Admission glucose-lowering agents | ||||
| Metformin, n (%) | 467 (72.3) | 80 (72.1) | 387 (72.3) | 0.955 |
| Sulfonylureas, n (%) | 166 (25.7) | 13 (11.7) | 153 (28.6) | 0.001 |
| DPP-4 Inhibitors, n (%) | 54 (8.4) | 8 (7.2) | 46 (8.6) | 0.630 |
| GLP-1 Agonist, n (%) | 19 (2.9) | 5 (4.5) | 14 (2.6) | 0.284 |
| In-hospital glucose-lowering strategy | ||||
| Insulin sc., n (%) | 430 (66.6) | 57 (51.4) | 394 (73.6) | <0.001 |
| Insulin iv., n (%) | 65 (10.1) | 17 (15.3) | 144 (26.9) | 0.010 |
| Discharge medical therapy (*) | ||||
| Anti platelets, n (%) | 621 (99.4) | 110 (99.1) | 511 (99.4) | 0.704 |
| DAPT, n (%) | 609 (97.4) | 109 (98.4) | 500 (97.3) | 0.577 |
| Anti coagulation, n (%) | 81 (12.5) | 10 (9) | 71 (13.3) | 0.217 |
| SRAA, n (%) | 416 (66.6) | 89 (80.2) | 409 (79.6) | 0.885 |
| Diuretics, n (%) | 271 (43.4) | 38 (34.2) | 233 (45.3) | 0.032 |
| B-blockers, n (%) | 545 (87.2) | 98 (88.3) | 445 (86.6) | 0.315 |
| CCB, n (%) | 147 (23.5) | 34 (30.6) | 113 (22) | 0.053 |
| Statins, n (%) | 587 (93.9) | 109 (98.2) | 495 (96.3) | 0.315 |
| Ezetimibe, n (%) | 118 (18.9) | 44 (39.6) | 210 (40.9) | 0.812 |
| Discharge glucose-lowering agents (*) | ||||
| Metformin, n (%) | 404 (64.6) | 83 (74.8) | 321 (62.5) | 0.014 |
| Sulfonylureas, n (%) | 137 (21.9) | 9 (8.1) | 128 (24.9) | <0.001 |
| DPP-4 Inhibitors, n (%) | 83 (13.3) | 13 (11.7) | 70 (13.6) | 0.591 |
| GLP-1 Agonist, n (%) | 26 (4.2) | 8 (7.2) | 18 (3.5) | 0.081 |
| Insulin sc., n (%) | 96 (15.4) | 8 (7.2) | 78 (15.2) | 0.027 |
RAAS = Renin-angiotensin-aldosterone system; CCB = Calcium channel blockers; DPP-4 = Dipeptidyl peptidase-4; GLP-1 = Glucagon-like peptide-1; sc. = subcutaneous; iv. = intravenous; DAPT = Dual Antiplatelet Therapy.
*
Percentages calculated on the number of patients discharged alive.